Navin Fluorine International Limited reported robust financial results for the quarter ended December 31, 2025 (Q3 FY26). Consolidated revenue grew by 47% year-on-year to INR892 crores, driven by strong momentum across all verticals. Operating EBITDA surged by 109% YoY, with margins improving to 34.5%. Significant milestones included the commissioning of the cGMP-4 Phase-1 and AHF projects, positioning the company well for future growth in advanced materials.
Q3 FY26 and Nine Months Performance Summary
Navin Fluorine International Limited announced its financial performance for the third quarter and nine months of FY26. For the quarter ending December 31, 2025, the company achieved a consolidated revenue of Rs.892 crores, marking a 47% year-on-year growth and an 18% sequential increase.
The operating performance showed significant leverage:
- Operating EBITDA stood at Rs.308 crores, a 109% YoY increase.
- EBITDA margins improved substantially to 34.5%, up from 24.3% in Q3 FY25.
- Profit After Tax (PAT) for the quarter grew by 122% YoY to INR185 crores.
For the nine-month period of FY26, revenue reached INR2,376 crores (a 44% growth over the previous year), with EBITDA margins improving to 32%. Notably, the company surpassed its full-year FY25 revenue within the first nine months of FY26.
Business Vertical Highlights
The strong results were attributed to consistent performance across all operating segments, supported by strategic CAPEX completion and strong order visibility.
HPP Business
The HPP business delivered consistent performance, with Q3 FY26 revenue at INR412 crores (35% YoY growth). The growth was fueled by higher realizations and improved volumes. The company confirmed the successful commissioning of the AHF project during Q4 FY26, with incremental R32 capacity expected in Q3 FY27.
Specialty Chemicals
This segment recorded its highest-ever quarterly revenue at INR354 crores in Q3 FY26, reflecting a 60% YoY increase. The success was driven by the Nectar ramp-up and scaling of existing molecules. The Chemours Project remains on track for completion in Q1 FY27.
CDMO Business
The CDMO segment demonstrated strong momentum, with revenue growing 61% YoY to INR127 crores. A key milestone achieved was the commencement of commercial supplies from the cGMP-4 facility to a European partner, providing strong revenue visibility over the next three years.
Advanced Materials and Future Outlook
Management highlighted positive developments in the Advanced Materials space, including initial evaluations for projects in the electronic chemical value chain. Policy support, such as the India’s Semiconductor Mission 2.0, is viewed as encouraging for this business.
The management stated that they expect the consolidated EBITDA margin run rate to stabilize around 30% plus or minus 200 basis points on an annualized basis. Furthermore, Wave-1 CAPEX projects (AHF, cGMP4) are complete, while Wave-2 projects (MPP debottlenecking, R32 expansion) are proceeding as planned.
Source: BSE
